Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera
Authors:
- Petros EliadisPEPetros Eliadis
- Annie MaisAMAnnie Mais
- Alexandros PapazisisAPAlexandros Papazisis
- Eleni K. LoxaELEleni K. Loxa
- Alexios DimitriadisADAlexios Dimitriadis
- Ioannis SarrigeorgiouISIoannis Sarrigeorgiou
- Marija BackovicMBMarija Backovic
- Maria AgallouMaria Agallou
- Marios ZouridakisMZMarios Zouridakis
- Evdokia KaragouniEKEvdokia Karagouni
- Konstantinos LazaridisKLKonstantinos Lazaridis
- Avgi MamalakiAMAvgi Mamalaki
Open Access
Abstract
Since the initiation of the COVID-19 pandemic, there has been a need for the development of diagnostic methods to determine the factors implicated in mounting an immune response against the virus. The most promising indicator has been suggested to be neutralizing antibodies (nAbs), which mainly block the interaction between the Spike protein (S) of SARS-CoV-2 and the host entry receptor ACE2. In this study, we aimed to develop and optimize conditions of a competitive ELISA to measure serum neutralizing titer, using a recombinant trimeric Spike protein modified to have six additional proline residues (S(6P)-HexaPro) and h-ACE2. The results of our surrogate Virus Neutralizing Assay (sVNA) were compared against the commercial sVNT (cPass, Nanjing GenScript Biotech Co., Nanjing City, China), using serially diluted sera from vaccinees, and a high correlation of ID50–90 titer values was observed between the two assays. Interestingly, when we tested and compared the neutralizing activity of sera from eleven fully vaccinated individuals who subsequently contracted COVID-19 (hybrid sera), we recorded a moderate correlation between the two assays, while higher sera neutralizing titers were measured with sVNA. Our data indicated that the sVNA, as a more biologically relevant model assay that paired the trimeric S(6P) with ACE2, instead of the isolated RBD-ACE2 pairing cPass test, could identify nAbs other than the RBD-RBM specific ones.Keywords
Funding Information
- Hellenic Pasteur Institute (14365/28, NSRF 2014–2020)
- Operational Program ‘Competitiveness, Entrepreneurship and Innovation’ (14365/28, NSRF 2014–2020)
- Greek Government and the European Union—European Regional Development Fund (14365/28, NSRF 2014–2020)
- Institut Pasteur, Urgence COVID-19 Fundraising Campaign of Institut Pasteur (14365/28, NSRF 2014–2020)
This publication has 82 references indexed in Scilit:
- Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibodyCell, 2022
- SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responsesCell, 2022
- Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over timeClinical & Translational Immunology, 2022
- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2Cell, 2021
- An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodiesCell, 2021
- B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoVCell, 2021
- Extremely potent human monoclonal antibodies from COVID-19 convalescent patientsCell, 2021
- BNT162b2 mRNA COVID-19 Vaccine: First ApprovalDrugs, 2021
- COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2021
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020